The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer--From "MAYBE" to "MUST BE".

Citation metadata

Date: Sept. 2021
From: Oncology(Vol. 35, Issue 9)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 1,040 words
Lexile Measure: 1820L

Document controls

Main content

Article Preview :

Remarkable advances in precision oncology over the last 2 decades have highlighted the necessity for genotyping in patients with advanced cancers to ensure appropriate therapy selection. Practice guidelines outlined by the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the Japanese Society of Medical Oncology now include recommendations for genotyping to guide therapy selection in different cancer types. (1-3) Although impressive progress has been achieved through the development of biomarker-targeted clinical trials, the pace of precision oncology innovations remains limited due to the daunting logistical realities of patient identification. Furthermore, because many actionable targets are present in only a small fraction of patients, hundreds or even thousands of patients need to be screened for enrollment in a single study. Compounding this patient identification barrier are the additional substantial challenges associated with traditional trial designs--such as the high cost of genotyping, lengthy screening periods, and limited access to screening populations--which collectively lead to increasingly low enrollment rates of otherwise eligible patients.

Patients with metastatic colorectal cancer (mCRC) are no exception. To date, several established and actionable genomic alterations have been identified in mCRC, including KRAS/NRAS mutations, BRAFV600E mutations, HER2 amplification, microsatellite instability-high or mismatch repair-deficient tumors, and NTRK fusions. (4) Additional targetable genomic alterations are emerging in mCRC, such as FGFR alterations, PIK3CA mutations, homologous recombination deficiency, MET amplification, and EGFR mutations. (4)

The COlorectal Cancer and Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy (COLOMATE; NCT03765736) trial discussed by Kristen K. Ciombor, MD, MSCI, and colleagues herein is a screening platform for mCRC developed by the Academic...

Source Citation

Source Citation   

Gale Document Number: GALE|A679525836